Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Stroke

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 83.3%Moderate 0 · 0%High 0 · 0%

Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

High‐dose VKA showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (low certainty).

1 finding from 1 review

Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

High‐dose VKA showed no clear difference in strokea compared with standard‐dose VKA (low certainty).

1 finding from 1 review

Any bleedingb · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

High‐dose VKA showed no clear difference in any bleedingb compared with standard‐dose VKA (low certainty).

1 finding from 1 review

Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

The review found no eligible studies for this question.

1 finding from 1 review

Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

High‐dose VKA showed no clear difference in any thromboembolic event compared with standard‐dose VKA (low certainty).

1 finding from 1 review

Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

High‐dose VKA showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).

1 finding from 1 review